Literature DB >> 23044176

Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.

Deirdre B Hoban1, Emer Connaughton, Catherine Connaughton, Grace Hogan, Chloe Thornton, Padraig Mulcahy, Teresa C Moloney, Eilis Dowd.   

Abstract

Chronic neuroinflammation has been established as one of the many processes involved in the pathogenesis of Parkinson's disease (PD). Because of this, researchers have attempted to replicate this pathogenic feature in animal models using the potent inflammagen, lipopolysaccharide (LPS), in order to gain better understanding of immune-mediated events in PD. However, although the effect of intra-cerebral LPS on neuroinflammation and neurodegeneration has been relatively well characterised, its impact on motor function has been less well studied. Therefore, the aim of this study was to further characterise the neuropathological and behavioural impact of intra-nigral and intra-striatal administration of LPS. To do, LPS (10 μg) or vehicle (sterile saline) were stereotaxically injected into the adult rat substantia nigra or striatum on one side only. The effect of LPS administration on lateralised motor function was assessed using the Corridor, Stepping and Whisker tests for two weeks post-injection, after which, amphetamine-induced rotational asymmetry was completed. Post-mortem, the impact of LPS on nigrostriatal degeneration and microgliosis was assessed using quantitative tyrosine hydroxylase and OX-42 immunohistochemistry respectively. We found that intra-nigral administration of LPS led to localised microgliosis in the substantia nigra and this was accompanied by nigrostriatal neurodegeneration and stable spontaneous motor deficits. In contrast, intra-striatal administration of LPS led to localised microgliosis in the striatum but this did not lead to any nigrostriatal neurodegeneration and only induced transient motor dysfunction. In conclusion, this study reveals the impact of intra-cerebral LPS administration on PD-related neuropathology and motor function, and it indicates that the intra-nigral model may be a highly relevant model as it is associated with stable motor decline underpinned by nigral microgliosis and nigrostriatal neurodegeneration.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23044176     DOI: 10.1016/j.bbi.2012.10.001

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  41 in total

1.  Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.

Authors:  Xiaohua Deng; Meili Li; Weiming Ai; Lixin He; Dahua Lu; Peter R Patrylo; Huaibin Cai; Xuegang Luo; Zhiyuan Li; Xiaoxin Yan
Journal:  Adv Alzheimer Dis       Date:  2014-06

2.  The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's Disease in Rats.

Authors:  Zhijuan Mao; Chanchan Liu; Suqiong Ji; Qingmei Yang; Hongxiang Ye; Haiyan Han; Zheng Xue
Journal:  Neurochem Res       Date:  2017-02-28       Impact factor: 3.996

Review 3.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

4.  LPS induces mediators of neuroinflammation, cell proliferation, and GFAP expression in human astrocytoma cells U373MG: the anti-inflammatory and anti-proliferative effect of guggulipid.

Authors:  Rituraj Niranjan; Rajasekar Nagarajan; Kashif Hanif; Chandishwar Nath; Rakesh Shukla
Journal:  Neurol Sci       Date:  2013-09-07       Impact factor: 3.307

5.  Biochanin A Protects Against Lipopolysaccharide-Induced Damage of Dopaminergic Neurons Both In Vivo and In Vitro via Inhibition of Microglial Activation.

Authors:  Jun Wang; Wang-Yang Wu; Huan Huang; Wei-Zu Li; Han-Qing Chen; Yan-Yan Yin
Journal:  Neurotox Res       Date:  2016-07-14       Impact factor: 3.911

Review 6.  Estrogens, Neuroinflammation, and Neurodegeneration.

Authors:  Alessandro Villa; Elisabetta Vegeto; Angelo Poletti; Adriana Maggi
Journal:  Endocr Rev       Date:  2016-05-19       Impact factor: 19.871

Review 7.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

8.  The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Authors:  Mark S Moehle; João Paulo Lima Daher; Travis D Hull; Ravindra Boddu; Hisham A Abdelmotilib; James Mobley; George T Kannarkat; Malú G Tansey; Andrew B West
Journal:  Hum Mol Genet       Date:  2015-04-29       Impact factor: 6.150

9.  Intraspinal TLR4 activation promotes iron storage but does not protect neurons or oligodendrocytes from progressive iron-mediated damage.

Authors:  Evan Z Goldstein; Jamie S Church; Nicole Pukos; Manoj K Gottipati; Phillip G Popovich; Dana M McTigue
Journal:  Exp Neurol       Date:  2017-08-26       Impact factor: 5.330

10.  Pharmacological targeting of β2 -adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease.

Authors:  Eoin O'Neill; Justin D Yssel; Caoimhe McNamara; Andrew Harkin
Journal:  Br J Pharmacol       Date:  2019-12-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.